Shares of Neurotrope Inc (NASDAQ:NTRP) have received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a 12-month consensus target price of $16.00 for the company, according to Zacks. Zacks has also given Neurotrope an industry rank of 190 out of 255 based on the ratings given to related companies.

Several equities research analysts have recently weighed in on NTRP shares. Zacks Investment Research raised Neurotrope from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Friday, August 17th. Maxim Group set a $16.00 price objective on Neurotrope and gave the stock a “buy” rating in a report on Thursday, July 12th. Finally, ValuEngine upgraded Neurotrope from a “hold” rating to a “buy” rating in a report on Tuesday, May 22nd.

NTRP traded up $0.21 during midday trading on Tuesday, hitting $8.69. 100 shares of the company traded hands, compared to its average volume of 9,252. Neurotrope has a 52 week low of $3.97 and a 52 week high of $11.93.

Neurotrope (NASDAQ:NTRP) last posted its earnings results on Friday, August 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.12.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Neville Rodie & Shaw Inc. bought a new position in Neurotrope during the second quarter valued at about $1,059,000. Cannell Peter B & Co. Inc. grew its position in shares of Neurotrope by 14.2% in the first quarter. Cannell Peter B & Co. Inc. now owns 270,793 shares of the company’s stock valued at $2,199,000 after purchasing an additional 33,600 shares during the last quarter. Tanaka Capital Management Inc. grew its position in shares of Neurotrope by 12.1% in the second quarter. Tanaka Capital Management Inc. now owns 198,195 shares of the company’s stock valued at $1,919,000 after purchasing an additional 21,455 shares during the last quarter. Ingalls & Snyder LLC acquired a new stake in shares of Neurotrope in the second quarter valued at about $326,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Neurotrope in the second quarter valued at about $281,000. Institutional investors own 16.83% of the company’s stock.

Neurotrope Company Profile

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Further Reading: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Neurotrope (NTRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.